Innovation / / 5 min read

WHO opens consultation on wearable health-surveillance standards as US FDA investigates Zolgensma gene therapy malignancy risk

The World Health Organization launched a public consultation on a draft Target Product Profile for wrist-worn wearables in population surveillance, while the FDA confirmed two cases of AAV vector integration into the GLI1 oncogene following Zolgensma therapy.

By 全球伯乐 News

Research and compilation

Share
On this page

AI-generated editorial illustration: a double-walled clear glass cube enclosing a helical ceramic capsule model on a flat limestone block, a dark-teal wrist strap loop, a metal stethoscope and a wooden-handled magnifying glass represent wearable surveillance standards and gene-therapy safety monitoring, not clinical samples.

AI-generated editorial illustration: a double-walled clear glass cube enclosing a helical ceramic capsule model on a flat limestone block, a dark-teal wrist strap loop, a metal stethoscope and a wooden-handled magnifying glass represent wearable surveillance standards and gene-therapy safety monitoring, not clinical samples.

WHO draft Target Product Profile for wrist-worn wearables: bridging consumer sensors and national health surveillance

The World Health Organization (WHO) launched a public consultation on November 8, 2026—running through December 6, 2026 at 12:00 UTC—on a draft Target Product Profile (TPP) for wrist-worn wearable devices intended to measure physical activity and sedentary behavior within national and subnational population health monitoring systems.1 Earlier the same week, on November 6, 2026, the U.S. Food and Drug Administration (FDA) issued a biologics safety communication announcing an investigation into postmarketing reports of malignancies in spinal muscular atrophy (SMA) patients treated with the adeno-associated virus (AAV) vector gene therapy Zolgensma, including confirmed cases of product-related insertional oncogenesis.2

In its November 8 consultation notice, WHO noted that while physical inactivity and sedentary behavior are major risk factors for noncommunicable diseases and poor mental health, objective wearable-based monitoring remains sparse in routine public health surveillance, particularly across low- and middle-income countries (LMICs).1 The draft TPP sets out both minimum and enhanced specifications for fit-for-purpose wrist-worn sensors alongside broader operational requirements for open data access, cross-country comparability and sustainable deployment in resource-constrained settings.1 The document is currently an open consultation draft rather than a binding procurement list or regulatory approval standard, with stakeholder feedback used to inform final consensus revisions after December 6.1

FDA investigation into Zolgensma insertional oncogenesis: molecular evidence of AAV integration at the GLI1 locus

In advanced biologics oversight, the FDA’s safety notice marks a transition from theoretical vector-integration warnings to molecularly confirmed clinical adverse events.2 FDA reported receiving postmarketing adverse event reports of tumors—spanning the central and peripheral nervous systems, spinal/paraspinal regions and kidney—in pediatric SMA patients treated with Zolgensma (onasemnogene abeparvovec, approved May 24, 2019 for intravenous infusion in children under 2 years of age).2 Crucially, three cases involved tumors associated with the GLI1 (Glioma-Associated Oncogene Homolog 1) oncogene; in two of those cases, molecular analysis of tumor tissue confirmed that Zolgensma AAV vector DNA integrated into the host genome with the construct’s promoter region inserted upstream of or within the GLI1 oncogene, while the mechanism in the third case remains under investigation.2

Citing two additional 2026 New England Journal of Medicine reports of AAV integration-driven tumors in other programs—a GLI1 integration event in the FBX-101 program (published October 15, 2026) and a PLAG1 integration event in the RGX-111 program (published June 4, 2026)—the FDA determined that the neoplasia risk applies to both onasemnogene abeparvovec products: Zolgensma and the intrathecally administered Itvisma (approved November 24, 2025 for SMA patients aged 2 years and older, which has no reported neoplasia cases to date) because both share the same vector and construct.2 The FDA emphasized that the overall benefits of Zolgensma and Itvisma continue to outweigh their risks for approved indications and has not suspended clinical use, but is evaluating prescribing-label updates and long-term follow-up requirements.2

Source notes

  1. 2026-11-08 · WHO invites feedback on a draft target product profile for wearable devices to measure physical activity and sedentary behaviour in population health monitoring systems · World Health Organization (WHO). ↩ ↩2 ↩3 ↩4

  2. 2026-11-06 · FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy · U.S. Food and Drug Administration (FDA). ↩ ↩2 ↩3 ↩4 ↩5 ↩6

Keep reading

More from the desk

Studio tabletop still life of three graduated brushed-brass blocks, a clear glass prism, and a dark green jadeite cylinder on veined white marble
Business/

EU Strikes Deal on Three-Tier 70% SFDR Sustainable Fund Categories as IMF Closes 58% of Open IEO Reform Actions

The Council of the European Union and the European Parliament reached a provisional agreement overhauling the Sustainable Finance Disclosure Regulation into sustainable, transition, and ESG basics categories with a 70% minimum investment threshold, while the IMF Executive Board concluded its 16th Periodic Monitoring Report on Independent Evaluation Office recommendations.

Studio tabletop still life of a clear glass microfluidic flow-cell slide, two amber glass reagent ampoules, and a brass cylinder on pale travertine stone
Innovation/

FDA Reviews Pathogen-Agnostic Sequencing Diagnostics as WHO GAP-f Advances Pediatric Medicines Roadmap and WIPO Signs 2027–2029 India IP Plan

The U.S. Food and Drug Administration Microbiology Devices Panel convened to evaluate pathogen-agnostic sequencing and agile bioinformatics for outbreak response, while the World Health Organization highlighted GAP-f pediatric formulation targets on World Children's Day and WIPO signed the 2027–2029 IP Action Plan with India covering AI analytics and dispute resolution.

Studio tabletop still life of a faceted clear optical glass cube, an unbranded titanium key blank, and a brass coaxial connector on dark basalt
Technology/

NIST Initiates TLS 1.3 Post-Quantum Revision and mDL Identity Guide as EU Launches First Cyber Resilience Act Standard and EDU-EDIC

The U.S. National Institute of Standards and Technology announced a major revision to SP 800-52 Rev. 2 for TLS 1.3 and post-quantum cryptography alongside draft SP 1800-42 for mobile driver licenses, while the European Commission published the first horizontal standard under the Cyber Resilience Act and launched the eight-nation EDU-EDIC digital education consortium.